Early clinical experience with atazanavir in treatment-experienced patients

Sexual Health

Volumn 3, Issue 1, 2006, Pages 33-35

  Jeganathan, Sarangapany ^a   Smith, Don ^a   Gold, Julian ^a  

^a Albion Street Centre ^*  (Australia)

Author keywords

Antiretroviral; HIV; Salvage therapy; Treatment experienced patients

Indexed keywords

ATAZANAVIR; BILIRUBIN; CHOLESTEROL; RITONAVIR; TRIACYLGLYCEROL;

ADULT; AMBULATORY CARE; ARTICLE; BILIRUBIN BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL PHARMACY; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HEALTH CARE ACCESS; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMATION PROCESSING; JAUNDICE; LETHARGY; MALE; MEDICAL DECISION MAKING; MEDICAL RECORD; NAUSEA; NEUROTOXICITY; PERIPHERAL NEUROPATHY; RETROSPECTIVE STUDY; TREATMENT FAILURE; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; BILIRUBIN; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; NEW SOUTH WALES; OLIGOPEPTIDES; PYRIDINES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 33144486509     PISSN: 14485028     EISSN: None     Source Type: Journal    
DOI: 10.1071/SH05022     Document Type: Article

References (10)

1. Becker S. Atazanavir: improving the HIV protease inhibitor class. Expert Rev Anti-infect Ther 2003; 1(3): 403-13. doi: 10.1586/14787210.1.3.403
2. Guffanti M, De Pascalis CR, Seminari E, Fusetti G, Gianotti N, Bassetti D, et al. Pharmacokinetics of amprenavir given once or twice a day when combined with atazanavir in heavily pre-treated HIV-positive patients. AIDS 2003; 17: 2669-70. doi: 10.1097/00002030-200312050-00017
3. Haas DW, Zala C, Schrader S, Piliero P, Jaeger H, Nunes D, et al. Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial. AIDS 2003; 17: 1339-49. doi: 10.1097/00002030-200306130-00008
4. Murphy RL, Sane I, Cahn P, Phanuphak P, Percival L, Kelleher T, et al. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS 2003; 17(18): 2603-14. doi: 10.1097/00002030-200312050-00007
5. Sanne I, Piliero P, Squires K, Thiry A, Schnittman S. A1424-007 Clinical Trial Group. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr 2003; 32: 18-29.
6. Wood R, Phanuphak P, Cahn P, Podrovsky V, Rozenbaum W, Panteleo G, et al. Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir. J Acquir Immune Defic Syndr 2004; 36(2): 684-92.
7. Barrios A, Rendon AL, Gallego O, Carbonero LM, Valer L, Rios P, et al. Predictors of virological response to atazanavir in protease inhibitor-experiencedpatients. HIV Clin Trials 2004; 5(4): 201-5.
8. Taburet AM, Piketty C, Chazallon C, Vincent I, Gerard L, Calvez V, et al. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2004; 48(6): 2091-6. doi: 10.1128/AAC.48.6.2091-2096.2004
9. Piliero PJ. Mechanisms of lipid elevations associated with the treatment of patients with HIV infection. Medscape General Medicine 2003; 5(2): 1-11.
10. Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Data collection on adverse events of anti-HIV drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349(21): 1993-2003. doi: 10.1056/NEJMoa030218